IV vitamin and drip therapy

1. Introduction

Version followed: elective, consumer-facing intravenous (IV) "nutrient", "hydration" or "wellness" infusions as offered by drip bars, IV lounges, medical spas, mobile and at-home services, including the Myers' cocktail and single-substance infusions of glutathione or NAD+, described as regulators and clinical references publish them (FTC, FDA, US state licensing boards, ASA/CAP, Ahpra, Merck Manual). The psychotherapist works alongside this method and does not perform, sell, prescribe or recommend IV therapy. Sections 1–3 describe the practice; section 4 is the therapist's own work alongside it.

What it is. IV vitamin therapy (also called IV micronutrient therapy or hydration therapy) puts a mixture of fluid, vitamins and minerals, and sometimes other substances, directly into a vein through a cannula, with the stated aim of raising blood levels faster and higher than taking them by mouth [source: Merck Manual, Intravenous Vitamin Therapy]. The Myers' cocktail is a vitamin-and-mineral formula popular with complementary and alternative medicine practitioners; it is named after a Baltimore physician, John Myers, and was popularised in the literature by Alan Gaby's 2002 paper in Alternative Medicine Review [source: Merck Manual cites Gaby 2002; origin details uncertain: not verified]. Medical spas and drip bars have popularised menus of named "cocktails" for hangover, energy, immunity, beauty, "detox" and anti-ageing [source: Merck Manual; Ahpra 2022].

How providers say change happens (attributed). Promoters hold that bypassing the gut delivers nutrients at higher concentrations, which they say boosts immunity, energy and mood, relieves stress, "detoxifies" the body, improves skin, rehydrates after exertion or alcohol, and helps a long list of conditions (asthma, migraine, fibromyalgia, diabetes, heart disease and others) [source: Merck Manual]. Glutathione infusions are marketed for appearance and "beauty" [source: Ahpra 2022]; NAD+ infusions are marketed for energy, "longevity" and anti-ageing [uncertain: not verified]. None of these is presented here as treating any disease.

Evidence status (one line). Scientific evidence is insufficient to confirm any of the promoted benefits or to show that IV vitamins treat any disease [source: Merck Manual].

Regulatory status (one line). In the US, adding vitamins or drugs to an IV bag is drug compounding and ordering it is the practice of medicine, so it needs a licensed prescriber's individual assessment and order; in the UK such products are not licensed medicines and may not carry medicinal claims; in Australia, Ahpra has warned that wellness IV advertising may breach the National Law [source: Wisconsin DSPS IAC 2025; Oregon State Board of Nursing 2024; ASA/CAP 2024; Ahpra 2022].

2. Framework

2a. The practice as clients meet it

Who provides it. Retail "on-demand" IV businesses (drip bars, IV lounges, medical spas, mobile and in-home services), some physician-owned clinics, and some integrative or anti-ageing practices [source: FDA 2021; Wisconsin DSPS IAC 2025]. Staffing varies; the infusion is not always given or supervised by a doctor [source: UCLA Health 2018].
What a client experiences. The client typically chooses a named drip from a menu, completes a health questionnaire, has a cannula placed in an arm vein, and sits or reclines while the bag runs, with a nurse checking on them; then the cannula is removed and they leave. Some businesses come to homes, hotels or events [source: Wisconsin DSPS IAC 2025; FDA 2021; Merck Manual; menu and seating details are general descriptions, synthesis]. Repeat visits and membership or package pricing are common in marketing [synthesis].
What licensing bodies require (US examples). A patient must be assessed by a qualified prescriber (physician, physician assistant or advanced practice nurse prescriber) before any IV treatment is ordered; standing orders are acceptable only within a genuine patient–practitioner relationship with individual assessment; nurses carry out the order and an RN monitors the client during the infusion; adding vitamins, minerals or drugs to bags is compounding governed by federal law (section 503A) and sterile-compounding standards; consent should cover the risks of the IV itself, the fluid and each additive [source: Wisconsin DSPS IAC 2025]. Oregon's nursing board states that a client cannot lawfully pick an IV mixture from a menu, because there is no legal authority for self-prescribing, and that no business can grant prescriptive authority to nurses [source: Oregon State Board of Nursing 2024]. Other US states vary, and some do not inspect or license these businesses [uncertain: not verified].
UK. IV nutritional therapies are distinct from IV medicines prescribed in primary or secondary care; medicinal claims are not allowed unless the product is licensed for that use, and prescription-only IVs and vitamin injections cannot be advertised to the public [source: ASA/CAP 2024]. The MHRA advised that any implied treatment or protection claim (e.g. COVID-19) brings the product under medicines regulation [source: ASA/CAP AdviceOnline]. Clinic registration requirements (e.g. CQC) [uncertain: not verified].
Australia. Ahpra and the National Boards enforce advertising rules (no false or misleading claims, restrictions on testimonials, no encouraging unnecessary use of health services); scheduled medicines (glutathione is listed by Ahpra as Schedule 4) are restricted under state and territory law; products and equipment are regulated by the TGA [source: Ahpra 2022].

2b. The psychotherapist's work alongside it

There is no published protocol for this; the structure below is [synthesis], built from general psychotherapy practice and the regulator material above.

Phase 1 – Notice and ask (any session). Goal: learn about IV use without judgement and record it. Move on when you know what, where, how often, who provides it and what the client hopes for.
Phase 2 – Understand (within ongoing sessions). Goal: meaning, hopes, explanatory model, social and commercial context. Move on when the client can say in their own words what they want from the drips and what else might meet that need.
Phase 3 – Decide and coordinate (as needed). Goal: an informed, values-based decision that is the client's; with consent, information shared with their GP or pharmacist. Move on when the client has a plan they own, including how they will judge it.
Phase 4 – Watch and review (ongoing, brief). Goal: recognise and respond to physical, psychological, financial and safeguarding risk; return to Phase 2 if use escalates or links to eating-disorder, health-anxiety or substance-use patterns.
Format. Integrated into ordinary individual sessions; no separate course. Return to the topic at reviews and when life events (illness, diet, new relationships or groups, money worries) change [synthesis].

3. Guiding principles

Curiosity, not verdicts. Ask the way you ask about sleep or alcohol; a client who feels judged stops telling you. [synthesis]
Stay in your scope. You do not perform, sell, prescribe, recommend or advise against a particular infusion, and you never advise on medicines; you route medical questions to the prescriber or pharmacist. [synthesis]
Attribute claims. Describe what providers claim as their claims ("the clinic says it boosts immunity"), and give evidence status plainly when asked [source: Merck Manual for evidence status].
It is a medical procedure. Elective drips are still IV medicine: a licensed prescriber's individual assessment, sterile preparation and monitoring are what regulators expect; a menu-and-go model without assessment is a warning sign, not a style choice [source: Wisconsin DSPS IAC 2025; Oregon State Board of Nursing 2024].
The need behind the drip matters more than the drip. Exhaustion, low mood, hangovers, body image and fear of illness are your territory; work on them directly. [synthesis]
Autonomy with information. Adults may choose lawful elective procedures; your job is to help the choice be informed and their own, not to win an argument. [synthesis]
Never instead of medical care. No infusion is a treatment for cancer or other physical disease; if a client is delaying or stopping prescribed care for it, that is a risk issue to address, with the doctor involved [source: FTC 2018 order and consumer notice].
Notice the market. Packages, memberships, influencer and testimonial marketing, and group or workplace "wellness" events shape decisions; name them neutrally. Testimonials are not accepted evidence for health claims by Ahpra [source: Ahpra 2022].
No conflicts of interest. You never sell, refer for commission or endorse IV businesses. [synthesis]
Record and coordinate with consent. Note use in the record like any other health behaviour; share with the GP or pharmacist only with consent, except where safeguarding or imminent risk overrides. [synthesis]

4. Intervention inventory

All interventions below are the psychotherapist's own work alongside a client's IV use. Steps and wording are [synthesis] unless a source tag says otherwise. Medical facts are given only as the cited clinical and regulatory sources state them.

4.1 Routine, non-judgemental inquiry and recording

Purpose / when. At intake, at reviews, and whenever a client mentions fatigue, hangovers, "detox", skin, weight, immunity or anti-ageing. Drips are often seen as lifestyle rather than medicine, so clients may not mention them unless asked.
Steps. (1) Ask within a general question about health practices, supplements and treatments. (2) If yes: what kind (named drip, glutathione, NAD+, "vitamin shot"), where (clinic, spa, mobile/home, event), how often, cost, who assessed them and whether a prescriber was involved. (3) Ask whether their GP or other doctors know. (4) Record factually in the notes as a health behaviour, without evaluative language. (5) Revisit at reviews.
Example language (illustrative). "Lots of people use things like supplements, vitamin drips or wellness treatments. Is anything like that part of your routine?" / "When you went for the drip, did anyone take a health history or check your medicines first?"
Watch for. Defensiveness (soften and normalise); escalating frequency or spend; use instead of medical care; drips at home or events with no prescriber contact (a regulatory warning sign: see 4.6). Working: the client mentions use spontaneously in later sessions.

4.2 Exploring meaning, hopes, expectations and explanatory model

Purpose / when. After use is known, or when a client is considering starting. Understanding what the drip does for the person shows what need you can work with directly.
Steps. (1) Ask what first drew them (an advert, friend, influencer, workplace or event, a clinic's suggestion). (2) Ask what they hope it does and how they will know. (3) Elicit their explanatory model of the problem it addresses (e.g. "I'm depleted", "toxins", "my immune system is weak", "I need to look younger"). (4) Explore functions: control, quick relief, reward or treat, identity and belonging, distrust of or disappointment with medicine, fear of illness or ageing. (5) Reflect back the underlying need in their words.
Example language (illustrative). "What does the drip give you that other things haven't?" / "If it worked exactly as you hoped, what would be different in your week?" / "You said the clinic told you it 'detoxes' – what does detox mean for you?"
Watch for. Expectations tied to disease treatment (cancer, MS, diabetes, heart failure, fibromyalgia were the conditions in the FTC's 2018 case) [source: FTC 2018]; drips used to undo drinking, restricting or purging; fear-driven use. Working: the client separates the need (rest, relief, reassurance, confidence) from the product.

4.3 Exploring the commercial and social context

Purpose / when. When packages, memberships, influencer content, group events or workplace wellness days are part of the picture.
Steps. (1) Map where the message came from and who profits. (2) Ask about spend relative to budget and any pressure to buy bundles or refer friends. (3) Describe, neutrally, that regulators have found claims in this market misleading and that testimonials are not accepted as evidence for health claims [source: Ahpra 2022; ASA/CAP 2024; FTC 2018]. (4) Explore social pressure: friends, partner, sports or gym culture, a group or community where drips signal belonging. (5) Invite the client to judge the message by their own standards.
Example language (illustrative). "Who do you hear about drips from, mostly?" / "How does the cost sit with the rest of your budget?" / "Some advertising regulators have said testimonials can't be used as proof a treatment works. How much did other people's stories shape your choice?"
Watch for. Debt, hiding spending, recruitment or reselling arrangements, a group that punishes doubt (see 4.9). Working: the client can describe the pressure without feeling attacked.

4.4 Supporting an informed, values-based decision

Purpose / when. When a client is deciding whether to start, continue or stop. You support the process; you do not recommend for or against the procedure. No specific published decision aid for IV wellness therapy is used here [uncertain: not verified].
Steps. (1) Clarify the decision and the client's values (health, safety, money, appearance, belonging). (2) Lay out what they already know and what they would want to know. (3) Offer, as general questions any consumer can ask a provider, the points regulators emphasise: Will a licensed prescriber assess me individually before anything is ordered? Who prepares the bag and where? Who monitors me during the infusion? What risks will I be told about for the IV, the fluid and each additive? [source: Wisconsin DSPS IAC 2025; Oregon State Board of Nursing 2024]. (4) Encourage them to put medical questions to their own doctor or pharmacist (see 4.5). (5) Summarise the decision as theirs, including how they will review it.
Example language (illustrative). "I'm not the person to say whether a drip is medically right for you. What I can do is help you think it through so the decision fits what matters to you." / "Licensing boards say someone qualified to prescribe should assess you first. Did that happen?"
Watch for. You drifting into advising (stop and refer); the client seeking your permission or prohibition; a decision driven by panic, shame or a sales deadline. Working: the client can state reasons in their own words and knows whom to ask about the medical side.

4.5 Coordinating with the client's doctor or pharmacist, with consent

Purpose / when. When the client has medical conditions, takes medicines, is pregnant or breastfeeding, or is using drips to manage a symptom that has not been medically assessed.
Steps. (1) Explain why sharing helps and ask for explicit consent, including what to share. (2) Encourage the client to tell the prescriber themselves first; offer a short written summary they can take. (3) With consent, contact the GP or pharmacist with facts only (what, how often, what for), no recommendation. (4) Note that clinical references list interactions for the prescriber to consider, for example IV vitamin B6 with erythropoiesis-stimulating drugs, magnesium with blood-pressure medicines, and IV calcium with the antibiotic ceftriaxone, and that safety in pregnancy and breastfeeding has not been studied [source: Merck Manual]; you name these only so the prescriber can review them, never as advice to the client. (5) Record consent and contact.
Example language (illustrative). "Your GP is the right person to check how the drips fit with your other medicines. Would you be willing to tell them, or would you like me to send a short note?"
Watch for. The client fearing the doctor's disapproval (explore it; offer to help them prepare); refusal (respect it unless risk overrides, record it). Working: the medical team knows, and the client feels supported rather than reported.

4.6 Recognising and responding to physical risk

Purpose / when. Any time a client reports a recent infusion and feels unwell, or describes an unsafe setting. You are not assessing medically; you recognise warning signs and route urgently.
Steps. (1) Know the warning signs the sources describe: fever, chills or shaking, nausea or vomiting, light-headedness, low blood pressure or difficulty breathing after an infusion (signs FDA linked to contaminated or endotoxin-laden products), and pain, redness or swelling at the site (vein inflammation, tissue damage) [source: FDA 2019 glutathione alert; UCLA Health 2018]. (2) If present: advise urgent medical care now (emergency services if breathing difficulty, fainting or confusion) and tell them to say they had an IV infusion and where. (3) Know who is at higher risk: people with heart failure or end-stage kidney disease, or on fluid restrictions, from extra fluid; people with abnormal magnesium or potassium, from heart-rhythm disturbance; and anyone receiving a product compounded in unsafe conditions [source: UCLA Health 2018; Merck Manual; FDA 2021]. (4) Note setting warning signs: no prescriber assessment, choosing a mixture from a menu, preparation outside a clean area, at-home or event service with no medical contact [source: Oregon State Board of Nursing 2024; FDA 2021]. (5) Document and consider reporting (4.11).
Example language (illustrative). "Fever and shaking after an infusion can be serious. I'd like you to get checked today – can you call now, while we're together?"
Watch for. Minimising ("it's just a reaction"); shame stopping the client from telling a doctor. Working: the client seeks care promptly and tells clinicians about the infusion.

4.7 Eating-disorder, body-image and "detox" screening

Purpose / when. When drips are framed around detox, fat loss, skin, appearance or "cleansing", or used after binges, restriction or heavy drinking. Advertisers have been told such claims (e.g. fat burning, cleansing organs, skin appearance) need robust evidence [source: ASA/CAP AdviceOnline 2024].
Steps. (1) Ask gently about eating, weight and shape concerns and compensatory behaviours. (2) Use a validated brief eating-disorder screener if you are trained in one, without reproducing items to the client in writing [synthesis]. (3) Explore orthorexic patterns: rigid "clean" rules, fear of contamination by food, use of drips as a substitute for eating or to "undo" eating. (4) If positive, follow your eating-disorder pathway: medical review for physical risk, specialist referral; cross-refer to the eating-disorder guides in this collection. (5) Explore body-image and ageing anxieties tied to glutathione or anti-ageing drips.
Example language (illustrative). "Sometimes people use drips to feel they've reset after eating or drinking. Does that fit for you at all?" / "How do you feel about your body when you skip the drip?"
Watch for. Restriction plus fluids-only "resets"; secrecy; weight loss; fainting. Working: the client can talk about eating and body without the drip as the frame.

4.8 Health anxiety, somatic symptoms and persistent fatigue

Purpose / when. When drips are sought for unexplained fatigue, "low immunity", brain fog or fear of illness, especially with frequent checking and reassurance-seeking. Cross-refer to Domain II for full protocols.
Steps. (1) Encourage medical assessment of the symptom if not done. (2) Formulate the cycle: symptom → threat interpretation → seeking a quick fix or reassurance → short relief → heightened monitoring. (3) Use established CBT-based approaches for health anxiety or persistent physical symptoms as described in Domain II (psychoeducation, attention and checking experiments, reducing reassurance-seeking, graded activity and pacing). (4) Treat each drip as one more data point in the cycle, not a target for prohibition. (5) Track function and wellbeing rather than symptom scans.
Example language (illustrative). "When the tiredness hits, what goes through your mind? And how long does the relief after a drip last before the worry comes back?"
Watch for. Doctor-shopping, escalating spend, avoidance of activity. Working: fewer reassurance-seeking acts, more tolerance of uncertainty, better function.

4.9 Recognising wider risk: children, pregnancy, alcohol, money and group pressure

Purpose / when. When the client's IV use involves dependants, pregnancy, alcohol, financial strain or a pressuring group.
Steps. (1) Children: if a child is being given infusions by a non-medical or wellness provider, or is being kept from medical care in favour of them, follow your safeguarding procedure; consider consent and the child's own assent [synthesis]. (2) Pregnancy and breastfeeding: note that safety has not been studied [source: Merck Manual]; encourage discussion with the midwife or obstetrician. (3) Alcohol: "hangover drips" can mask a drinking pattern; screen for alcohol use and offer evidence-based alcohol work. Clinicians do use vitamin infusions for suspected malnutrition in heavy alcohol use, which is a medical matter for the treating team [source: Merck Manual]. (4) Money: ask about debt, credit, pressure to buy packages. (5) Group pressure: ask whether doubt is tolerated; whether leaving would cost relationships; whether the group sells products or trainings. Cross-refer to Domain XII commerce and group-dynamics guidance.
Example language (illustrative). "You mentioned you book a drip most Sundays after a big Saturday. Could we look at the Saturdays for a moment?"
Watch for. Concealment, a partner or group controlling choices, children presenting with unexplained IV marks or illness. Working: risks are named, and protective steps are in place.

4.10 Boundaries and conflicts of interest

Purpose / when. Always; especially if you work in a multidisciplinary wellness or medical-spa setting, or a client asks your opinion or a referral.
Steps. (1) Do not sell, promote, take commission on, or refer to IV businesses. (2) If your workplace offers drips, declare this to clients, keep your role separate, and decline to discuss purchases in therapy. (3) Answer "should I?" questions by returning to the decision process (4.4) and the prescriber (4.5). (4) Notice your own views (enthusiasm or contempt) and keep them out of the room. The profession's ethics code on conflicts of interest applies [uncertain: not verified; synthesis].
Example language (illustrative). "I keep out of recommending treatments like this either way – it's outside my role, and I don't want my view to crowd out yours."
Watch for. Pressure from employers to cross-sell; clients wanting you to "bless" a choice. Working: clear, consistent role boundaries the client understands.

4.11 Reporting routes

Purpose / when. When a client has been harmed, a setting appears unsafe, an unqualified person is giving infusions, disease-treatment claims are being made, or a child is at risk. Explain options; with consent, help the client report; report yourself where your duties require.
Steps. (1) Medical emergency first (4.6). (2) Choose the route:
- US: adverse events or quality problems with compounded products to FDA MedWatch [source: FDA 2019; FDA 2021]; false or unsupported health claims to the FTC (ftc.gov/complaint) [source: FTC 2018]; practitioners and nurses to the state medical, nursing or pharmacy board, which treat these services as the practice of medicine with defined nursing and compounding rules [source: Wisconsin DSPS IAC 2025; Oregon State Board of Nursing 2024].
- UK: misleading advertising to the ASA [source: ASA/CAP 2024]; medicines and side-effects to the MHRA (Yellow Card scheme) [uncertain: not verified]; professional concerns to the relevant regulator (GMC, NMC, GPhC) [uncertain: not verified].
- Australia: concerns about a registered practitioner, or someone falsely claiming to be one, to Ahpra; products, IV equipment and fluids to the TGA [source: Ahpra 2022].
- Mexico: COFEPRIS investigates health risks from such products [source: La Crónica de Hoy 2026]; reporting mechanism [uncertain: not verified].
- Safeguarding: your local child or adult safeguarding procedure where a child or adult at risk is given harmful procedures or deprived of medical care [synthesis]. (3) Record what was reported, to whom, and the client's consent or the reason consent was overridden.
Example language (illustrative). "What happened to you could help regulators protect other people. Would you like to go through the reporting form together?"
Watch for. Fear of retaliation or embarrassment; the client being bound by a non-disclosure or membership agreement (encourage legal advice) [synthesis]. Working: the client feels in control of the report.

4.12 Supporting a client after a harmful infusion

Purpose / when. After infection, sepsis, hospital admission, an injury at the site, or bereavement following an infusion.
Steps. (1) Check medical follow-up is in place. (2) Assess for acute stress and PTSD symptoms after hospital or intensive care, and for depression [synthesis]. (3) Address shame and self-blame ("I chose it"), separating responsibility for choosing a legal service from responsibility for unsafe practice. (4) Support practical steps: complaints, reporting, legal advice, money. (5) For bereaved family members, offer grief work that holds anger at the provider and any family conflict about the choice.
Example language (illustrative). "You chose a service you were told was safe. What happened in that clinic wasn't yours to control."
Watch for. Intrusive memories of the reaction, avoidance of all medical care (including necessary IVs), anger turning inward. Working: the client can seek medical care again and tell the story without overwhelming shame.

5. Handling problems

No source addresses psychotherapy alongside IV drips; all guidance here is [synthesis] unless tagged.

"Everyone does it; you're being paranoid." Agree it is common, return to the client's own aims, and ask what would tell them it is working. Avoid debating evidence; offer the one-line evidence status only if asked [source for evidence status: Merck Manual].
Client wants you to say it's fine (or to forbid it). Name the role boundary (4.10), then return to their values and the prescriber's input (4.4–4.5).
Client stopping or delaying prescribed treatment for drips. Treat as a risk issue: explore the fear or disappointment behind it, ask for consent to involve the doctor, and say plainly that drips are not a treatment for disease. The FTC required one seller to tell customers studies had not shown its cocktail treats the diseases it named, and not to stop prescribed treatment without their provider [source: FTC 2018]. If the client lacks capacity or a child is affected, safeguarding applies.
Escalating frequency or spend. Map it as a coping or compulsive pattern (relief-seeking, reward, avoidance); use motivational interviewing to explore ambivalence; check for debt; look for a primary problem (alcohol, eating disorder, health anxiety, depression).
Rupture after you raise risk. Acknowledge it directly ("I may have sounded like I was telling you off"), restate respect for their choice, and repair before returning to the topic later.
Client unwell during or after a session following an infusion that day. Pause therapy, check for warning signs (4.6), arrange urgent care; do not continue as usual.
Client works in or owns a drip business. Explore role stress, ethical strain or legal worries as they bring them; do not advise on their business's compliance; signpost professional or legal advice.
Disagreement in families or couples about drips. Use systemic or couple-work skills: each person's fears and hopes, shared values, money agreements; keep medical questions with the doctor.
Your own reaction. If you find yourself contemptuous or evangelical, take it to supervision; the client will sense it.
Cultural or community meaning. Some clients use injections or drips within cultural traditions of care or beauty; explore respectfully and avoid assumptions [synthesis; uncertain: not verified in sources].
Overwhelm after a frightening reaction. Ground first, focus on safety and medical follow-up, then trauma-informed processing later (4.12).

Harm account

Administration is described only qualitatively; no contents, rates or preparation details are given. Private individuals are not named.

What was actually done

Disease-treatment claims at a drip-bar chain (US, 2018). A & O Enterprises, doing business as iV Bars, owned and operated by Aaron K. Roberts, ran clinics in north Texas (including Addison and Southlake), New Braunfels, Texas, and Vail, Colorado, selling "iV Cocktails", including a Myers Cocktail, as water, vitamins, minerals and herbs put into the bloodstream, at $100 or more per session. Marketing claimed they treated cancer, congestive heart failure, multiple sclerosis, diabetes, fibromyalgia and neurodegenerative disorders, gave fast and lasting results, were often more effective and better tolerated than conventional treatment, and were scientifically proven. The FTC alleged these claims were false or unsupported; in its first action against IV cocktail therapy (announced 20 September 2018, final order approved February 2019) the order barred such claims without competent and reliable scientific evidence, and the company had to email buyers that studies had not shown the cocktail treats the named diseases and that they should not stop prescribed treatment without their provider [source: FTC press release 2018].
Insanitary compounding in clinics (US, 2016–2021). FDA described medical offices and clinics, and newer models such as IV hydration clinics, medical spas and mobile IV services, preparing sterile products in unsafe conditions. Examples FDA gave: an oncology practice (2016) where 17 of 38 exposed patients developed a fungal infection linked to soiled material in a compounding hood placed near a sink; the Guyer Institute of Molecular Medicine (inspected July 2020), where staff in street clothes filled sterile products outside a clean area, with damaged filters, peeling surfaces and expired ingredients, shipping products nationwide; and Age Management Institute Santa Barbara (February 2021), where a woman in her fifties was hospitalised with suspected septic shock and multi-organ failure after an at-home IV vitamin infusion whose blood cultures grew Pseudomonas fluorescens, and inspectors found no certified clean area, carpet in the IV mixing room, dirty vents and standing water in a refrigerator storing sterile vials [source: FDA 2021].
Supplement-grade glutathione injected (US, 2019). A repackager, Letco Medical (Decatur, Alabama), supplied L-glutathione powder labelled "Caution: Dietary Supplement" that pharmacies compounded into injectables. In January 2019 seven patients at one outpatient clinic developed nausea, vomiting, light-headedness, chills, body aches and sneezing within minutes of an IV injection; one had low blood pressure and difficulty breathing and went to hospital. In February 2019 another patient, given glutathione compounded by a different pharmacy, was admitted with sudden chills, fever and shaking and a possible bloodstream infection. FDA testing found excessive bacterial endotoxin in all samples [source: FDA 2019].
Unproven wellness infusions (Australia, 2022). Ahpra warned that clinics were marketing IV "cocktails" for immunity, mental clarity, beauty and anti-ageing, including glutathione, with marketing outpacing evidence, and wrote to several businesses whose advertising may breach the National Law [source: Ahpra 2022].
COVID-19 and benefit claims (UK, 2020–2023). The ASA ruled against IV drip advertisers (including Cosmetic Medical Advice UK, The Private Harley Street Clinic and Reviv UK) for COVID-19 medicinal claims in April 2020, and issued further IV nutritional therapy rulings in December 2023 [source: ASA/CAP 2024].
Fatal "vitamin" infusions (Mexico, 2026). In Hermosillo, Sonora, patients of a private clinic, some treated in private homes, received IV solutions marketed as containing vitamins and also "stem cells". By 7 April 2026 health authorities reported 11 suspected cases linked to one doctor: 8 deaths, one in hospital and two discharged; some worsened within hours, others died after days in hospital. Patients showed signs of sepsis; bacterial contamination was the main line of investigation, with samples analysed in coordination with COFEPRIS. The clinic was closed and the state prosecutor opened a criminal investigation [source: La Crónica de Hoy 2026].

How it caused harm

Contamination and endotoxin. Products prepared outside clean conditions, or from ingredients not made for injection, delivered bacteria, fungi or endotoxin straight into the blood, causing fever, chills, low blood pressure, bloodstream infection, septic shock, multi-organ failure and death [source: FDA 2021; FDA 2019; La Crónica de Hoy 2026; Merck Manual]. FDA notes adverse events from these settings are likely under-reported [source: FDA 2021].
The IV procedure itself. Infection, damage to tissue around the site, vein inflammation and air entering the bloodstream (air embolism) [source: UCLA Health 2018].
Fluid and electrolytes. Extra fluid can seriously harm people with congestive heart failure, end-stage kidney disease or fluid restrictions; abnormal magnesium or potassium can cause heart-rhythm disturbance or muscle weakness; infusing too quickly can cause low blood pressure, dizziness or fainting [source: UCLA Health 2018; Merck Manual].
Additive effects and interactions. Side effects or overdose from vitamins or minerals [source: UCLA Health 2018]; interactions with erythropoiesis-stimulating drugs, blood-pressure medicines and ceftriaxone [source: Merck Manual]; unknown safety in pregnancy and breastfeeding [source: Merck Manual].
Indirect harm. Claims of treating cancer, heart failure, MS or diabetes risk people delaying or abandoning effective treatment [source: FTC 2018 order wording; harm mechanism synthesis]. Repeated spending on unproven benefits causes financial harm [synthesis].
Who was most at risk. People with heart or kidney disease, electrolyte problems or on interacting medicines; pregnant or breastfeeding people; people with serious illness seeking hope; and anyone receiving infusions at home or in unregulated settings without prescriber assessment [source: UCLA Health 2018; Merck Manual; FDA 2021; synthesis for the last group].

Recognising it today

Features and phrases. A menu of named drips chosen by the customer; claims to "boost immunity", "detox", "cleanse vital organs", "burn fat", give energy, "calm your mind" or improve skin; cure or prevention claims for named diseases or COVID-19; "scientifically proven"; testimonials as proof; implied lasting benefit from one infusion [source: ASA/CAP AdviceOnline 2024; FTC 2018; Ahpra 2022].
Red flags in a setting or colleague's practice. No individual assessment by a licensed prescriber; nurses or others prescribing; mixing in an ordinary room, a home or an event; ingredients sourced as dietary supplements; no monitoring during the infusion; staff falsely presenting as doctors or nurses; "vitamin" products mixed with stem-cell or other exotic claims [source: Oregon State Board of Nursing 2024; Wisconsin DSPS IAC 2025; FDA 2019; FDA 2021; Ahpra 2022; La Crónica de Hoy 2026].
Rebrandings. IV hydration, IV nutritional therapy, IV micronutrient therapy, IV lounge, drip spa, recovery, hangover, beauty, glow, longevity or NAD+ drips, "vitamin shots" [source: Merck Manual; ASA/CAP 2024; naming variants partly synthesis].
How legitimate IV therapy differs. Clinicians use IV fluids and vitamins for diagnosed problems, for example suspected malnutrition in heavy alcohol use, after medical assessment, with prescribing, sterile preparation and monitoring under clinical governance [source: Merck Manual; Wisconsin DSPS IAC 2025].

What to do instead and how to help those harmed

Safer alternatives (for the need, not the drip). Medical assessment for fatigue, dehydration or suspected deficiency, with treatment the doctor chooses; a diet-focused approach, which a UCLA family physician described as likely safer, cheaper and quicker [source: UCLA Health 2018]; psychological work on the underlying need (stress, low mood, alcohol, eating, body image, health anxiety) using sections 4.2–4.9.
Assessment of affected clients. Confirm medical follow-up; screen for post-hospital and post-ICU stress, depression and avoidance of necessary medical care; assess financial harm; ask about children or others exposed [synthesis].
Treatment. Trauma-focused work where PTSD criteria are met; grief work for bereaved families, including anger and family conflict about the choice; shame and self-blame work (4.12) [synthesis].
Ethical, reporting and legal duties. Support reporting to FDA MedWatch, the FTC, state boards, the ASA, Ahpra or the TGA as relevant (4.11); follow safeguarding procedures where children or adults at risk are involved; keep clear records; do not give legal advice but signpost it; never name or discuss other clients or victims [source: FDA 2019; FDA 2021; FTC 2018; Ahpra 2022; ASA/CAP 2024; safeguarding and legal steps synthesis].

Sources

← Previous · XII-136Non-medical chelation and provoked-urine testing Next · XII-138 →Ozone therapy